CombiGene ended all R&D and employment after a strategic review, posting a SEK 44.9 million net loss for 2024. The company retains a strong cash position and will focus on investments or potential dividends, given challenging biotech market conditions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.